Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus

Lei Huang¹, Yuan Tan² and Yilong Pan¹*

¹Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China; ²Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China

Abstract

Aims Left ventricular thrombus (LVT) increases the risk of thrombotic events and mortality. Vitamin K antagonists (VKAs) used to treat LVT have several known risks, as a result of which direct oral anticoagulant (DOAC) use has recently increased. We aimed to evaluate the safety and efficacy of DOACs and VKAs in treating LVT.

Methods and results We searched PubMed, Embase, Cochrane Library trials, and Web of Science databases for studies published before 19 April 2022, involving DOAC versus VKA treatment for patients with LVT. This meta-analysis comprised 21 studies (total patients, n = 3172; DOAC group, n = 888; VKA group, n = 2284). A statistically significant reduction in bleeding events was observed in patients on DOACs vs. those on VKAs (risk ratio (RR) = 0.73, P = 0.004). Patients on DOACs residing in North American and European regions and those with ischaemic heart disease (IHD) had a significantly lower risk of bleeding events than patients residing in other regions or those with a different LVT aetiology, respectively (RR = 0.78, P = 0.04; RR = 0.38, P = 0.02; and RR = 0.63, P = 0.009). A statistically significant reduction in stroke in patients on DOACs versus VKAs (RR = 0.72, P = 0.03) was observed, and patients on DOACs residing in North America and those with IHD had a significantly lower risk of stroke (RR = 0.73, P = 0.04, and RR = 0.61, P = 0.03, respectively). Compared with VKAs, DOACs are statistically associated with an increase in LVT resolution at 1 month (RR = 1.96, P = 0.008). No statistical between-group difference in all-cause mortality (RR = 0.72, P = 0.05), systemic embolism (RR = 0.87, P = 0.74), stroke or systemic embolism (RR = 0.90, P = 0.50), and LVT resolution at the end of follow-up (RR = 1.06, P = 0.13) was observed.

Conclusions Compared with VKAs, DOACs significantly reduce the risk of bleeding events and stroke in LVT patients, but mortality was similar in both groups. The advantages are apparent not only in patients belonging to the predominantly white residential areas such as North American and European regions but also in patients with LVT due to IHD. DOACs show promising effects in treating LVT compared with VKAs.

Keywords Direct oral anticoagulants; Left ventricular thrombus; Vitamin K antagonist; Systematic review

Received: 24 March 2022; Revised: 5 July 2022; Accepted: 18 July 2022

*Correspondence to: Yilong Pan, Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang 110004, China. Fax: 024-23899651. Email: panyilong505@163.com

Introduction

Left ventricular thrombus (LVT) is a common and serious complication following acute myocardial infarction (AMI) and in those with severe left ventricular systolic dysfunction.¹⁻³ If left untreated, LVT has been reported to markedly increase composite stroke or systemic embolism (SSE) rates.⁴ Current consensus guidelines recommend the use of vitamin K antagonists (VKAs) such as warfarin for 3 to 6 months in patients with LVT following AMI.⁵⁻⁶ However, warfarin’s disadvantages, including its slow onset of action, the frequent need to monitor the international normalized ratio (INR), the constant adjustment of the dose to achieve the therapeutic window, and noted drug-to-drug or
drug-to-food interactions, may influence patient adherence and contribute to the increasing global use of direct oral anticoagulants (DOACs).7–10

DOACs may be an optimal alternative to VKAs as they have a fast onset of action, a stable drug concentration, no requirement to determine the INR, fewer interactions, and a lower rate of bleeding events.9 As first-line drugs, DOACs are currently used to prevent thrombus formation in patients with non-valvular atrial fibrillation (AF) and deep vein thrombosis.11,12 However, DOACs are used off-label as anticoagulant treatment in patients with LVT. To date, several case studies, observational studies, and randomized control trials (RCTs) have suggested analogous or contradictory safety and efficacy when comparing DOACs with VKAs to treat LVT.13–34 A few meta-analyses have drawn varied conclusions in terms of efficacy and safety between DOACs and VKAs,35,36 predominantly suggesting that DOACs use may be promising when treating patients with LVT. However, no RCTs were included in the meta-analysis of Xuan et al.35 resulting in a lack of clinical evidence. Almost 50% of the studies included in the study by Michael et al. involved abstracts without complete experimental data,36 which may influence the generalizability of their results. Moreover, more studies comparing DOACs and VKAs in the treatment of LVT have been published recently.15,22,24,26,27,30–34 We aimed to undertake a systematic review and meta-analysis to evaluate the safety and efficacy of DOACs versus VKAs in the management of LVT in terms of clinical outcomes for all-cause mortality, bleeding events, stroke, systemic embolism (SE), SSE, and LVT size reduction or resolution particularly focusing on subgroup analyses by region and aetiology.

Methods

Search strategy and data sources

Two investigators (L. H. and Y. T.) systematically searched PubMed, Embase, Cochrane Library trials, and Web of Science core collection databases for related studies published before 19 April 2022. The PubMed search items were: (Factor Xa inhibitor OR direct thrombin inhibitor OR oral anticoagula* OR antithrombin OR NOAC OR DOAC OR dabigatran OR Pradaxa OR Rendix OR ximelagatran OR Exanta OR melagatan OR rivaroxaban OR edoxaban OR apixaban OR betrixaban OR darexaban OR Xarelto OR eliquis OR lixiana) AND ([(left ventricle* OR LV) AND (thromb* OR clot) OR LVT]). The PubMed search strategy is shown in the Supporting Information, Table S1. We also searched ClinicalTrials.gov for unfinished studies as well as related study references to avoid omitting any relevant studies.

Inclusion and exclusion criteria

The inclusion criteria were studies (i) involving patients with a confirmed diagnosis of LVT; (ii) that compared DOACs with VKAs; (iii) in which efficacy and safety outcomes were available; and (iv) that were RCTs or observational studies.

The exclusion criteria were (i) studies not published in English and (ii) publications such as case studies, posters, abstracts, systematic reviews, or meta-analyses.

Data extraction and quality assessment

Two authors (L. H. and Y. T.) independently extracted the following information from the included studies: baseline study data (study title, first author, year of publication, publication type, and patient region), patient demographic data (median age, sex, region, and related primary disease), study design, method of diagnosis, sample size, interventions, follow-up durations, and study outcomes. Any discrepancies between L. H. and Y. T. concerning the included studies were resolved through discussions, and a third author (Y. L. P.) was consulted to help resolve any disagreements.

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews.37 The Cochrane Collaboration’s tool was used to assess bias in RCTs, and the Newcastle-Ottawa Scale (NOS) was used to assess the quality of the observational studies.38,39

Data analysis

We used RevMan software version 5.4 and Stata/MP 16.0 to combine and analyse outcomes from the included studies.14–34 Risk ratios (RRs) with 95% confidence intervals (CIs) were used to evaluate differences between patients in the DOACs and VKAs groups. We used a random-effects model to pool all of the outcomes. A Q test was utilized to assess heterogeneity between studies, and an I² > 50% was deemed to indicate significant heterogeneity.40 We set a P-value <0.05 as statistically significant. Contour-enhanced funnel plot symmetry, trim and fill analysis (metatrim), and Egger’s tests were used to evaluate the publication bias of the included studies in the meta-analysis.41 Sensitivity analyses were undertaken to estimate the influence of a single study on the whole assessment. We also performed subgroup analyses according to the region (North America, Europe, East Asia, and Middle East regions and Africa) or aetiology (ischaemic heart disease IHD, proportion >50%). IHD is defined by the incidence of coronary artery disease (CAD), myocardial ischaemia, and myocardial infarction (MI), including its complications.42

DOI: 10.1002/ehf2.14084

ESC Heart Failure 2022; 9: 3519–3532
Results

Literature search

In total, 2632 studies were identified in four databases, involving 555 studies from PubMed, 1231 from Embase, 156 from the Cochrane Library trials, 688 from Web of Science core collection, and 2 from reference lists and ClinicalTrials.gov. We first removed all duplicates. We reviewed the titles and abstracts and then excluded reviews, letters, case reports or case series, comments, animal studies, trials with no LVT treatment, studies with designs that did not compare between DOAC and VKA treatments, and study protocols with no experimental data. We identified 39 studies for further filtering by browsing the full text. Finally, 21 studies meeting the inclusion criteria were included in this meta-analysis. The literature search and selection process, conducted in accordance with PRISMA guideline standards, is shown in Figure 1.

Characteristics and quality of included studies

Baseline characteristics are shown in Table 1. The 21 included studies, comprising 3 RCTs and 18 cohort studies had been published between 2019 and 2022. Studies were mainly conducted in North America, Europe, Africa, and Asia. In total, 3172 patients (DOAC group: 888 patients and VKA group: 2284 patients) were included in the meta-analysis. Rivaroxaban and apixaban were preferred among the DOACs used (rivaroxaban, apixaban, edoxaban, or dabigatran), and warfarin was preferred among the VKAs used (warfarin, acenocoumarol, or fluindione). The mean patient age ranged from 50 to 66 years, and 76.9% of the patients were males. Ischaemic cardiomyopathy (ICM) and AMI were found to be the major aetiologies of LVT. Most studies had used transthoracic echocardiography (TTE) to diagnose LVT, while some studies had used cardiac magnetic resonance imaging (CMRI) or others as auxiliary diagnostic methods. Follow-up duration ranged between 3 and 44 months. Thirteen studies

Figure 1: A flowchart indicating the literature search and study selection process. DOACs, direct oral anticoagulants; LVT, left ventricular thrombus; VKAs, vitamin K antagonists.
Table 1  Summary of basic characteristics and risk of bias assessment concerning the included cohort studies

| Author (year) | Region | Design | Sample size (VKAs (n) DOACs (n)) | Mean age (years) | Male (%) | Follow up (months) | Aetiology of LVT | Diagnose method | Target INR (%) | Drug combination | Outcome | Risk of bias assessment of cohort studies |
|---------------|--------|--------|----------------------------------|------------------|----------|-------------------|-----------------|-----------------|----------------|----------------|---------|------------------------------------------|
| Abdelnabi (2021) | Egypt and Bulgaria | RCT | Warfarin (40) Rivaroxaban 20 mg QD (39) | 50 | 57 | 6 | ICM (78.5%) Idiopathic (20.3%) Peripartum (1.2%) | TTE | NC | NC | Antiplatelet (53.1%) | Bleeding events Stroke, SE, SSE LVT resolution | *** * |
| Albabtain (2021) | Saudi Arabia | Retrospective | Warfarin (35) Rivaroxaban 15/20 mg QD (28) | 59 | 92 | 14 | MI HF CM | TTE 2–3 | 82.3 | Aspirin (61.9%) Clopidogrel (53.97%) | Bleeding events Stroke, SE, SSE Mortality LVT resolution | *** * *** |
| Alcalai (2021) | Israel | RCT | Warfarin (17) Apixaban 5 mg BID (18) | 57 | 80 | 3 | AMI (100%) | TTE 2–3 bridged with LMWH | 60 | According to physician | | |
| Ali (2020) | USA | Retrospective | Warfarin (60) Rivaroxaban (18) Apixaban (13) Dabigatran (1) | 59 | 79 | 12 | ICM (58%) Non-ICM (23%) AMI (15%) Takotsubo CM (3%) | TTE CC CTA MRI | NC | NC | Aspirin (65.45%) Clopidogrel (14.55%) Ticagrelor (0.91%) Prasugrel (1.82%) | Bleeding events Stroke, SSE | *** * ** |
| Bass (2021) | USA | Retrospective | Warfarin (769) Apixaban (79) Rivaroxaban (77) Dabigatran (29) DOACs (14) | 62 | 71 | 3 | MI (54.8%) | NC | NC | NC | Antiplatelet (54%) | Bleeding events Stroke, SSE | *** * * |
| Cochran (2021) | USA | Retrospective | Warfarin (59) | 60 | 77 | 12 | AMI (48%) | TTE | NC | NC | NC | |
| Daher (2020) | France | Retrospective | Warfarin (14) Fludione (16) Acenocoumarol Apixaban (12) Dabigatran (1) | 62 | 84 | 3 | ICM (86.5%) DCM (13.5%) | TTE 2–3 | NC | NC | Aspirin (64.4%) P2Y12 inhibitor (47.5%) | Bleeding events Stroke, SSE Mortality LVT resolution | *** * * |

(Continues)
Table 1 (continued)

| Author         | Year | Region          | Design       | VKAs (n) | DOACs (n) | Sample size | Mean age (years) | Male (%) | Follow up (months) | Aetiology of LVT | Diagnose method | TTR (%) | Drug combination | Target INR | TTR | Outcome | Risk of bias assessment of cohort studies |
|----------------|------|-----------------|--------------|----------|-----------|-------------|------------------|----------|--------------------|----------------|----------------|---------|-----------------|-----------|-----|---------|----------------------------------------|
| Guddeti (2020) | USA  | Retrospective   | Warfarin (80)| Apixaban (15) Dabigatran (2) Rivaroxaban (2) | 61           | 71           | 12               | AMI (20.2%) | ICM (58.6%) | TTE | NC | NC | P2Y12 inhibitor (15.2%) | Triple therapy (13.1%) | NC | Bleeding events | Stroke, SSE LVT resolution | LVT resolution |
| Herald (2022)  | USA  | Retrospective   | Warfarin (299)| Dabigatran (108) Rivaroxaban (6) Apixaban (20) | 66           | 83           | 41               | NC | TTE | NC | NC | Bleeding events | Stroke, SSE LVT resolution | LVT resolution |
| Iqbal (2020)   | UK   | Retrospective   | Warfarin (62)| Rivaroxaban 20 mg QD (13) Apixaban 5 mg BID (8) Dabigatran 150 mg BID (1) | 62           | 75           | 36               | ICM (87%) | MI (35%) | DCM (5%) | HCM (4%) | TTE | TOE | Contrast-TTE CMR | 2–3 bridged with LMWH | NC | Bleeding events Stroke, SSE Mortality LVT resolution |
| Iskaros (2021) | USA  | Retrospective   | Warfarin (45)| Apixaban (24) Rivaroxaban (7) Dabigatran (1) | 62           | 90           | 3                | NC | TTE | TEE | CT | CMR | 2 bridged with LMWH | Antiplatelet (66%) | NC | Bleeding events Stroke, SSE Mortality LVT resolution |
| Jones (2021)   | UK   | Prospective     | Warfarin (60)| Rivaroxaban (24) Apixaban (15) Edoxaban (2) | 60           | 85           | 18               | AMI (100%) | TTE CMR | 2–3 | NC | Triple therapy (69.3%) | Bleeding events Stroke, SSE Mortality LVT resolution |
| McCarthy (2019)| USA  | Retrospective   | Warfarin (94)| Apixaban (3) Rivaroxaban (1) | NC | NC | 44               | HF (68.5%) | AMI (25.9%) | TTE | Contrast - TTE | TTE CMR | NC | NC | NC | Bleeding events Stroke, SSE Mortality LVT resolution |
| Mihm (2021)    | USA  | Retrospective   | Warfarin (75)| Apixaban (23) Rivaroxaban (10) | 61           | 77           | 6                | NC | TTE | NC | NC | NC | Bleeding events Stroke, SSE Mortality LVT resolution |
| Ratnayake (2020)| NZ   | Retrospective   | Warfarin (42)| Dabigatran (2) | 55           | 37           | 6                | AMI (100%) | TTE | 2–3 bridged with LMWH | NC | Aspirin (85%) | Clopidogrel (42%) | NC | Bleeding events Stroke, SSE Mortality LVT resolution |

(Continues)
| Author (year) | Region | Design | Sample size | Mean age (years) | Male (%) | Follow up (months) | Aetiology of LVT | Diagnose method | Target INR (%) | Drug combination | Outcome | Risk of bias assessment of cohort studies |
|--------------|--------|--------|-------------|-----------------|---------|-------------------|-----------------|-----------------|----------------|----------------|----------|----------------------------------------|
| Robinson (2020) | USA | Retrospective | Warfarin (236) DOACs (121) | 58 | 74 | 12 | ICM (59.9%) | TTE | NC | NC | Bleeding events | *** ** *** |
| Vanvani (2021) | Kenya | Retrospective | Warfarin (34) Rivaroxaban (46) Dabigatran (7) Apixaban (5) | 61 | 77 | 24 | Post MI (28%) ICM (42%) Non-ICM (30%) | TTE | NC | 13.1 | NC | Bleeding events | *** * *** |
| Willeford (2021) | USA | Retrospective | Warfarin (129) Apixaban (4) Rivaroxaban (18) | 56 | 80 | 8.5 | HF (85.4%) MI (25.8%) | 2–3 bridged with parenteral therapy | NC | Aspirin (49.7%) P2Y12 inhibitor (2.5%) | Bleeding events | **** * ** |
| W. Isa (2020) | Malaysia | RCT | Warfarin (13) Apixaban 5 mg BID/2.5 mg BID (14) | 55 | 93 | 3 | NC | 2–3 bridged with LMWH | NC | NC | Mortality Size reduction of LVT | - |
| Xu (2021) | China | Retrospective | Warfarin (62) Rivaroxaban (16) Dabigatran (9) | 62 | 79 | 28 | ICM (75.9%) | TTE | 2–3 | Aspirin (43.7%) | Bleeding events Stroke, SE, SSE Mortality LVT resolution | *** * ** |
| Zhang (2021) | China | Retrospective | Warfarin (31) Rivaroxaban (33) | 60 | 59 | 25 | AMI (100%) | TTE | 2–2.5 | NC | Triple therapy (100%) | *** * ** |

AMI, acute myocardial infarction; BID, twice daily dosing; CC, cardiac catheterization; CM, cardiomyopathy; CMRI, cardiovascular magnetic resonance imaging; CTA, computed tomography angiography; DOAC, direct oral anticoagulant; HF, heart failure; ICM, ischaemic cardiomyopathy; INR, international normalized ratio; LVT, left ventricular thrombus; MI, myocardial infarction; MRI, magnetic resonance imaging; NC, not clear; QD, once-daily dosing; RCT, randomized controlled trial; SE, systemic embolism; SSE, stroke or SE; TTE, transthoracic echocardiogram; TTR, time in therapeutic range for the warfarin; TOE, trans-oesophageal echocardiography; VKA, vitamin K antagonist.

The risk of bias assessment for the cohort studies was performed using the Newcastle-Ottawa Scale indicating points for cohort studies. A study could be awarded a maximum of 4 stars (*) for selection, 2 stars (*) for comparability, and 3 stars (*) for the outcome.
described a combination treatment using antiplatelet drugs.\textsuperscript{14,15,17,18,20,21,23,25,28,31–34} We assessed the quality of RCTs according to the Cochrane risk of bias tool,\textsuperscript{38} as shown in the Supporting Information, Figure S1. We used the NOS to assess the quality of cohort studies,\textsuperscript{39} as shown in Table 1.

Outcomes

Main safety outcomes

Ten studies mentioned all-cause mortality as an important safety endpoint of LVT treatment.\textsuperscript{15,16,19,22,23,27,29,32–34} Among these studies, 14.0% of patients on DOACs and 22.3% of patients on VKAs had died, but no statistical difference was observed between the two groups (RR = 0.72, 95% CI = 0.52–1.00, \( P = 0.05 \), \( I^2 = 11\% \); Figure 2A). Bleeding events, as the main safety endpoint of LVT treatment, were reported in 16 studies.\textsuperscript{14–16,18,19,21–25,27,29–31,33,34} In those studies, 10.9% of patients treated with DOACs and 14.3% of patients treated with VKAs were reported to have had bleeding events with a significant difference between the two groups (RR = 0.73, 95% CI = 0.58–0.90, \( P = 0.004 \), \( I^2 = 0\% \); Figure 2B,C). Based on the principle of geographical proximity, we divided the included studies into four regional subgroups: North America, Europe, East Asia, and Middle East regions and Africa. After stratification according to patient region, further analysis indicated that the rate of bleeding events in patients receiving DOACs was markedly inferior to that in those being treated with VKAs among patients residing in North America, mainly including the United States of America (USA) (RR = 0.78, 95% CI = 0.61–0.99, \( P = 0.04 \), \( I^2 = 0\% \); Figure 2B) and in European countries mainly including the United Kingdom (UK) (RR = 0.38, 95% CI = 0.17–0.83, \( P = 0.02 \), \( I^2 = 0\% \); Figure 2B). We also analysed subgroups in terms of the incidence of bleeding events, stratified according to the aetiology of LVT, and observed that the incidence of bleeding events in the DOACs group was significantly lower than that in the VKA group among patients with IHDs (RR = 0.63, 95% CI = 0.44–0.89, \( P = 0.009 \), \( I^2 = 0\% \); Figure 2C).

Main efficacy outcomes

The occurrence of stroke, an important efficacy outcome of LVT treatment, was reported in 14 studies.\textsuperscript{14,15,17–19,21–25,27,30,31,33} Stroke occurrence was 7.4% in patients on DOACs versus 11.6% in patients on VKAs. A statistically significant reduction in the incidence of stroke was found when comparing patients on DOACs with those on VKAs (RR = 0.72, 95% CI = 0.54–0.96; \( P = 0.03 \), \( I^2 = 0\% \); Figure 3A, B). We similarly divided the included studies into four regional subgroups: North America, Europe, East Asia, and Middle East regions and Africa. The subgroup analysis indicated that the risk of stroke in patients being treated with DOACs was markedly inferior to those receiving VKAs among patients residing in North America, primarily including the USA (RR = 0.73, 95% CI = 0.54–0.99, \( P = 0.04 \), \( I^2 = 0\% \); Figure 3A). We also analysed subgroups in terms of the incidence of stroke, stratified according to the aetiology of LVT, and observed that the incidence of stroke in the DOACs group was significantly lower than that in the VKAs group among patients with IHD (RR = 0.61, 95% CI = 0.39–0.96, \( P = 0.03 \), \( I^2 = 0\% \); Figure 3B).

Ten studies\textsuperscript{14,15,17,22–24,27,31,33,34} reported SSE data, in which SSE occurred in 1.4% of patients on DOACs and 2.4% of patients on VKAs; however, this between-group difference was not statistically significant (RR = 0.87, 95% CI = 0.37–2.02, \( P = 0.74 \), \( I^2 = 0\% \); Figure 3C). Eighteen studies\textsuperscript{14–25,27,29–31,33,34} reported SSE outcomes, in which SSE occurred in 13.5% of patients on DOACs compared with 19.6% of patients on VKAs; however, SSE occurrences did not differ significantly between the two groups (RR = 0.90, 95% CI = 0.65–1.23, \( P = 0.50 \), \( I^2 = 23\% \); Figure 3D).

Eighteen studies\textsuperscript{14–17,19–21,23–31,33,34} reported LVT resolution, one study\textsuperscript{32} reported LVT size reduction, and three studies\textsuperscript{14,17,34} reported thrombus resolution rates at 1 month. LVT resolution was reported for 65.8% of patients on DOACs and for 63.2% of patients on VKAs. LVT size reduction was reported in 65.1% of patients on DOACs and in 61.5% of patients on VKAs, and LVT resolution at 1 month occurred in 46.2% of patients on DOACs and in 22.1% of patients on VKAs. No statistical differences were found between the two groups in terms of LVT resolution (RR = 1.06, 95% CI = 0.98–1.13, \( P = 0.13 \), \( I^2 = 0\% \); Figure 3E) or LVT size reduction (\( P = 0.82 \)). However, a statistically significant increase in LVT resolution at 1 month follow-up was found for patients on DOACs when compared with those on VKAs (RR = 1.96, 95% CI = 1.19–3.22, \( P = 0.008 \), \( I^2 = 31\% \); Figure 3F).

Publication bias and sensitivity analysis

Contour-enhanced funnel plots for outcomes were drawn, and no asymmetry was detected when they were assessed using Egger’s regression (bleeding events: \( P = 0.64 \); stroke: \( P = 0.52 \); SE: \( P = 0.95 \); SSE: \( P = 0.08 \); LVT resolution: \( P = 0.75 \); Figure 4). We conducted sensitivity analyses for the main endpoints to assess the robustness of the results by sequentially eliminating one study. Remarkable differences were noted when we tested the mortality data after excluding studies by Robinson et al., Iqbal et al., Mihm et al., and Xu et al.\textsuperscript{19,23,27,34} Subsequently, we found significant differences when the stroke data was tested after excluding studies by Bass et al. and also when we tested the LVT resolution data after excluding studies by Robinson et al.\textsuperscript{18,29} No remarkable differences were found when we tested the data of bleeding events, SE, and SSE.
Figure 2 A Forest plot of mortality and bleeding events. (A) Mortality; (B) bleeding event subgroups stratified according to region; (C) bleeding event subgroups stratified according to LVT aetiology. CI, confidence interval; df, degrees of freedom; DOACs, direct oral anticoagulants; M-H, Mantel–Haenszel; LVT, left ventricular thrombus; VKAs, vitamin K antagonists.

(3526) L. Huang et al. ESC Heart Failure 2022; 9: 3519–3532 DOI: 10.1002/ehf2.14084

### (A) North America

| Study or Subgroup | DOACs | VKAs | Total | Weight | M.L. Random, 95% CI | Risk Ratio M.L. Random, 95% CI |
|------------------|-------|------|-------|--------|---------------------|-------------------------------|
| Israel 2021      | 3     | 3    | 6     | 3.0    | 0.89 (0.40, 1.90)   | 0.72 (0.40, 1.32)             |
| Coxdrin 2021     | 3     | 3    | 6     | 3.0    | 0.72 (0.40, 1.32)   | 0.72 (0.40, 1.32)             |
| Guidetti 2020    | 1     | 1    | 2     | 1.0    | 1.68 (0.89, 3.19)   | 0.72 (0.40, 1.32)             |
| New 2021         | 4     | 2    | 6     | 3.0    | 1.68 (0.89, 3.19)   | 0.72 (0.40, 1.32)             |
| Robinson 2021    | 4     | 2    | 6     | 3.0    | 1.68 (0.89, 3.19)   | 0.72 (0.40, 1.32)             |
| Xu 2021          | 2     | 2    | 4     | 2.0    | 1.68 (0.89, 3.19)   | 0.72 (0.40, 1.32)             |
| Zhang 2021       | 1     | 1    | 2     | 1.0    | 1.68 (0.89, 3.19)   | 0.72 (0.40, 1.32)             |
| Total (95% CI)   | 482   | 482  | 964   | 482    | 0.72 (0.53, 1.00)   | 0.72 (0.53, 1.00)             |
| Total events     | 62    | 178  | 240   | 120    |                     |                               |
| Heterogeneity    | Test for overall effect = Z = 1.86 (P = 0.06) |

### (B) East Asia

| Study or Subgroup | DOACs | VKAs | Total | Weight | M.L. Random, 95% CI | Risk Ratio M.L. Random, 95% CI |
|------------------|-------|------|-------|--------|---------------------|-------------------------------|
| Israel 2021      | 0     | 2    | 2     | 1.0    | 0.62 (0.32, 1.20)   | 0.62 (0.32, 1.20)             |
| Jones 2021       | 0     | 4    | 4     | 2.0    | 0.62 (0.32, 1.20)   | 0.62 (0.32, 1.20)             |
| Subtotal (95% CI)| 63    | 122  | 185   | 92     | 0.62 (0.32, 1.20)   | 0.62 (0.32, 1.20)             |
| Total events     | 6     | 28   | 34    | 17     |                     |                               |
| Heterogeneity    | Test for overall effect = Z = 2.43 (P = 0.02) |

### (C) Middle East and Africa

| Study or Subgroup | DOACs | VKAs | Total | Weight | M.L. Random, 95% CI | Risk Ratio M.L. Random, 95% CI |
|------------------|-------|------|-------|--------|---------------------|-------------------------------|
| Israel 2021      | 2     | 2    | 4     | 2.0    | 0.62 (0.32, 1.20)   | 0.62 (0.32, 1.20)             |
| Jones 2021       | 0     | 2    | 2     | 1.0    | 0.62 (0.32, 1.20)   | 0.62 (0.32, 1.20)             |
| Subtotal (95% CI)| 58    | 110  | 168   | 84     | 0.62 (0.32, 1.20)   | 0.62 (0.32, 1.20)             |
| Total events     | 3     | 5    | 8     | 4.0    |                     |                               |
| Heterogeneity    | Test for overall effect = Z = 3.22 (P = 0.00) |

### (D) Subgroup Differences

Test for subgroup differences: CHF: Z = 3.11, df = 3 (P = 0.00), P = 3.7%
Discussion

LVT formation has been reported to complicate 1.6–39% of AMIs during the acute phase and remains common in patients with severely impaired left ventricular systolic function. With the timely treatment of emergency percutaneous coronary intervention (PCI) and the improvement of perioperative management, the incidence of left ventricular thrombosis after MI decreased substantially. However, the overall incidence of LVT in anterior ST-segment elevation myocardial infarction (STEMI) patients is 12.2%, while the incidence of LVT in anterior STEMI patients with left ventricular ejection fraction (LVEF) < 50% is as high as 19.2%. LVT is associated with serious embolic complications as thrombi may flow downstream into the arterial system, resulting in devastating stroke events, SE, and SSE. Furthermore, it is also associated with detrimental cardiac events and increased mortality, which may be attributed to delayed reperfusion, severe myocardial damage, and lower LVEF. Mechanisms of LVT development after AMI mainly include endothelial injury in the area of MI, blood stasis caused by decreased ventricular contractility, and hypercoagulability triggered by inflammation. Therefore, anticoagulation represents an important therapeutic target. However, anticoagulation
treatment concurrently carries a potential risk of bleeding; therefore, it is essential that patient management can balance the risks and benefits of such treatment.

VKAs have a good anticoagulant effect with widely inhibiting the activation of coagulation factors (II, VII, IX, X) and proteins (C, S). Warfarin is the most commonly used and recommended VKA in the treatment of LVT; however, its use requires frequent monitoring and dosage adjustment. Moreover, its slow action and interaction with drugs and food may reduce patient adherence, influence the therapeutic effect, and decrease patient quality of life. DOACs are highly selective direct inhibitors of coagulation factor Xa or thrombin and do not require patient monitoring. Considering the major advantages of DOACs compared with VKAs, in terms of the clinical benefits observed in patients with AF and venous thromboembolism, such as lower rates of intracranial haemorrhage and bleeding events, stable drug concentration, and ease of administration, there has recently been considerable interest in the use of DOACs to treat LVT. However, their use in LVT treatment has still not been recommended in guidelines owing to a lack of evidence.

In this evidence-synthesis study, we evaluated the safety and efficacy of DOACs for patients with LVT. Our analysis included 3172 patients in 21 studies and showed that DOACs might be a better treatment option than warfarin for LVT treatment, especially in patients residing in North American and European regions or those with a diagnosis of IHD.

Our findings suggest that all-cause mortality rates were similar among differing oral anticoagulants. Owing to the small sample sizes in most of the included studies and the differing follow-up durations, evidence concerning mortality rates may have been affected. When we conducted sensitivity analyses for mortality data, we noted remarkable differences after excluding studies by Cochran et al., Iqbal et al., Mihmet et al., and Xu et al. These four studies are limited due to small sample size. In contrast, among the studies mentioning mortality, the study by Herald et al. had a large sample size (DOACs: 134 vs. VKAs: 299) and a relatively long follow-up time (median of 3.4 years). It concluded that the mortality in the DOACs group was significantly lower than that in the VKAs group (P = 0.008).

Significant inferior rates in terms of the occurrence of bleeding events in the DOACs group versus VKAs group were identified in our study. The bleeding occurrence was lower for patients residing in North American and European regions, and patients with IHD treated with DOACs than patients residing in other regions or those with a different LVT aetiology, respectively. Our findings concerning bleeding events were influenced by several factors that may have affected our conclusions. First, several studies have shown a similar risk reduction across ethnic groups in terms of major bleeding events involving patients on DOACs compared with those on VKAs. In the North American subgroup, the average white population accounts for a relatively high proportion.
according to the studies by Ali et al., Bass et al., Herald et al., Mihn et al., and Robinson et al. (68.5%, 74.3%, 45.0%, 75.9%, and 53.8%, respectively).\textsuperscript{17,18,22,27,29} Tedla et al.\textsuperscript{49} recently conducted a study in America and reported that DOACs significantly reduced the incidence of bleeding only in white patients compared with VKAs. Lähteenmäki et al. reported that ABCB1 variants are potential factors affecting bleeding events in apixaban users.\textsuperscript{50} Zhao et al. concluded that interindividual differences in bleeding events induced by rivaroxaban might be potentially driven by genetic alterations related to abnormal metabolism and transport of rivaroxaban.\textsuperscript{51} Therefore, consideration of ethnic and genetic factors may be important when evaluating the risk of bleeding. Second, an antiplatelet therapy strategy is necessary for patients with LVT and IHD, and dual antiplatelet therapy significantly reduces the occurrence of stroke in patients with LVT and IHD.\textsuperscript{52} VKAs, especially in white patients. Subsequently, it may be attributed to the low or uncertain rate of reaching the INR standard on VKAs, as mentioned by Ali et al.\textsuperscript{17,25} When conducting sensitivity analyses for stroke, we found significant differences after excluding the study conducted by Bass et al.\textsuperscript{18} This study had the largest sample size and its findings on the outcome of stroke were consistent with most other studies.\textsuperscript{14,17,19,21–23,25,30,31,33} The incidence of stroke in the DOACs group was lower than that in the VKAs group. Therefore, there is a need for more studies with a large sample size to make further robust conclusions.

No significant difference was detected in terms of the incidence of SE between patients taking DOACs (1.4% of patients) and those taking VKAs (2.4% of patients). Our outcome was possibly affected by several factors, such as the small sample sizes and very low morbidity rates for SE following treatment. After synthesizing all the included studies that mentioned SSE, no difference was found between patients in either group, whereas in Ali et al.’s\textsuperscript{17} cohort study and Abdelnabi et al.’s\textsuperscript{14} RCT, the incidence of SSE was significantly reduced in DOACs groups compared with VKAs groups ($P = 0.0001$ and $P = 0.01$, respectively); however, given the small sample sizes in these studies, further large-scale RCTs are needed to validate these findings.

Although no distinction in LVT resolution was found between the two groups on completion of the follow-up period, a statistically significant increase in LVT resolution at 1 month was found in patients on DOACs versus VKAs (46.2% vs. 22.1%). Two studies conducted by Albabtain et al.\textsuperscript{15} and Iskaros et al.\textsuperscript{24} mentioned a shorter time of thrombus resolution in the DOACs group compared with that in the warfarin group ($P = 0.019$ and $P = 0.003$, respectively). Isa et al.\textsuperscript{32} conducted an RCT and found an increased size reduction in LVT in patients in the DOAC group than those in the VKAs group without a statistical difference ($P = 0.816$). McCarthy et al.\textsuperscript{26} found that thrombus resolution occurred in 100% who received DOACs compared with 75% who received warfarin. DOACs directly act on factor Xa or thrombin, and their rapid action allows for faster thrombus resolution. Even after warfarin began to manifest its action, DOACs were found to be at least as effective as warfarin in the entire follow-up period. However, the difference in size reduction or LVT resolution between the two groups was influenced by the therapeutic target of INR (TTR), diagnosis method, and the follow-up duration. The sub-optimal TTR may affect the resolution rate of LVT on VKAs, as mentioned in studies conducted by Alcalai et al., Ratnayake et al., Zhang et al.\textsuperscript{16,28,34} One previous study recommended performing LVT imaging using delayed enhancement CMRI and transesophageal echocardiography, with follow-up time points in the range of 3–12 months.\textsuperscript{36} The diagnostic methods and follow-up duration of the included studies were not entirely consistent, which may have influenced our findings. Despite this consideration, we suggest adding a 1 month time-point to the follow-up, which may reduce the treatment duration for some patients.

All the aforementioned outcomes suggest equal or better safety and efficacy of DOACs versus VKAs in LVT treatment.
Although DOACs are not currently recommended as a first-line treatment for LVT, our meta-analysis adds strength and power to current recommendations and provides support for potentially expanding the use of DOACs in LVT. The current evidence suggests that DOACs achieve the same or better clinical outcomes than VKAs in LVT treatment; however, further prospective large-scale RCTs are required to obtain more robust clinical evidence.

Study limitations

This meta-analysis had several limitations. First, the included studies did not use a uniform DOACs regimen, and different DOACs may have different efficacy and safety levels. Second, our meta-analysis included only 3 RCTs and 18 observational cohort studies, mainly including studies with small sample sizes. Hence, more high-quality, large-scale, randomized clinical trials are required to validate our findings. Third, the following factors critical for the assessment of outcomes remain to be elucidated: the LVT diagnostic method, which may be better confirmed using delayed enhancement CMRI or transesophageal echocardiography; dual antiplatelet therapy strategies, which directly affect bleeding and stroke outcomes; the TTR, which directly influences the effects of VKAs; the follow-up duration, which is important when determining mortality and LVT resolution rates; and DOAC types and dosages, which may affect individual efficacy. Finally, we defined the IHD group as the number of IHD patients was higher than 50% in the study population, possibly representing a confounding factor; we used regional classification as an indirect racial classification, because only few studies mentioned the race of the patients.

Conclusions

Mortality of patients with LVT was similar for DOACs and VKAs, but, compared with VKAs, DOACs significantly reduce the risk of bleeding events and stroke in LVT patients. The advantages are apparent not only in predominantly white residential areas such as North America and European regions but also in patients with LVT owing to IHD. Moreover, compared with VKAs, DOACs are statistically associated with an increase in LVT resolution at 1 month. This meta-analysis showed that DOACs are likely to be promising candidates for LVT treatment compared with the recommended VKAs.

Acknowledgement

The authors thank Xiaolei He for her excellent assistance with data collection.

Conflict of Interest

The authors declare there are no competing interests.

Funding

This work received financial support from the Liaoning Educational Committee Program (Grant No. JGZR20200012), the Cardiovascular Multidisciplinary Integrated Research Fund (z-2016-23-2101-15), and the 345 Talent Project of Shengjing Hospital.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Randomized controlled trials risk of bias assessment

The Cochrane risk of bias tool was used to assess the risk of bias in the randomized controlled trials.

“the study met the domain criterion; it was unclear whether the domain criterion had been met; “the study did not meet the domain criterion

Table S1. Search strategy for PubMed

Abbreviations: NOAC, novel oral anticoagulants; DOAC, direct oral anticoagulants; LVT, left ventricular thrombus

References

1. McCarthy CP, Vaduganathan M, McCarthy KJ Jr, JLJ, Bhatt DL, McEvoy JW. Left ventricular thrombus after acute myocardial infarction: Screening, prevention, and treatment. JAMA Cardiol. 2018; 3: 642–649.

2. Talle MA, Bubaf, Anjorin CO. Prevalence and Aetiology of left ventricular thrombus in patients undergoing transthoracic echocardiography at the University of Maiduguri Teaching Hospital. Adv Med 2014; 2014: 731956, 1, 8.

3. Habash F, Vallurupalli S. Challenges in management of left ventricular thrombus. Ther Adv Cardiovasc Dis. 2017; 11: 203–213.

4. Kernan WN, Ovbiagele B, Black HR, Bravata WM, Chimowitz MI, Ezekowitz
Efficacy of direct oral anticoagulants in left ventricular thrombus

MD, Fang MC, Fisher M, Furie KL, Heck WV, Johnston SCC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45: 2160–2236.

5. O’Gara PT, Kushner FG, Ascheim DD Jr, DEc, Chung MK, Lemos JAD, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamiis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yaney CW. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013; 127: 362–425.

6. Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio APL, Crea F, Gourdeau VA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39: 119–177.

7. Patel PA, Zhao X, Fonarow GC, Lyle BL, Smith EE, Xian Y, Bhatt DL, Peterson ED, Schwamm LH, Hernandez ADF. Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack. Circ Cardiovasc Qual Outcomes. 2012; 5: 823–32.

8. Loo SY, Dell’Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017; 83: 2096–2106.

9. Ruft CT, Giugliano RP, Braunwald E, Hoffman EB, Deedwania P, Ezekowitz MD, Camm AJ, Weijtzi L, Lewis PS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials. Lancet. 2014; 383: 955–962.

10. Shi B, Wang H, Song C, Yin D, Wang H, Dou KF, Song W. Widespread off-label use of direct oral anticoagulants in patients with left ventricular thrombus. J Am Coll Cardiol. 2022; 79: 1028.

11. Hindricks G, Potpara T, Dagen R, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, Meir ML, Lane DA, Lebeau J, Lettinno M, Lip GYH, Pinto EF, Thomas GN, Valgimigli M, Gelder IVC, Putte BPV, Watkins CL. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio-thoracic surgery (EACTS). Eur Heart J. 2020; 42: 373–498.

12. Wang Y, Lv H, Li D, Chen C, Gu G, Sun Y, Yang X, Liu Y, Fang F, Liu J, Tse G, Xia Y. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer-associated thrombosis: A systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. Front Pharmacol. 2019; 10: 773.

13. Tomasoni D, Sciami E, Bonelli A, Vizzardi MF. Direct Oral anticoagulants for the treatment of left ventricular thrombosis—a new indication? A meta-summary of case reports. J Cardiovasc Pharmacol. 2020; 75: 530–534.

14. Abdelnabi M, Saleh Y, Fareed A, Nussinov A, Wang L, Morsi M, Eshak N, Abdelwahab O, Badr H, Almaghraby A. Comparative study of oral anticoagulation in left ventricular thrombi (N-IVT trial). J Am Coll Cardiol. 2021; 77: 1590–1592.

15. Alabtain MA, Alhebaishi Y, Al-Yafi O, Kheirallah H, Ohman A, Alghoosoon H, Arafat AA, Alhebaishi Y, Al-Yafi O, Rashad R, Ibrahimli M, Planer D, Civitelli A, Alamgir A. Rivaroxaban versus warfarin for the management of left ventricular thrombus. Egyptian Heart Journal. 2021; 73: 41.

16. Alcali R, Butmuru A, Moravsky G, Yagel O, Rashad R, Ibrahimli M, Planer D, Amir O, Elbaz-Greener G, Leibowitz D. Rivaroxaban versus warfarin for left ventricular (LV) thrombus, a prospective randomized trial. Eur J Heart J Cardiovasc Pharmacother. 2021; 19: 57.

17. Ali Z, Isom N, Dalia T, Sami F, Mahmood U, Shah Z, Gupta K. Direct oral anticoagulants use for left ventricular thrombus. Thromb J. 2020; 18: 29.

18. Bass ME, Kiser TH, Page RL 2nd, McIver I, Allen LA, Wright G, Shakkow S. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021; 52: 517–522.

19. Cochran JM, Jia X, Kaczmarek Z, Staggers KA, Rifai MA, Hamzeh IR, Birnbaum Y. Direct oral anticoagulants in the treatment of left ventricular thrombus: A retrospective, multicenter study and meta-analysis of existing data. J Cardiovasc Pharmacol Ther. 2021; 26: 173–178.

20. Daher J, Costa A, Hilaire C, Ferreira T, Pierrard R, Guichard JB, Romeyer C, Issaz K. Management of left ventricular thrombus with direct oral anticoagulants: Retrospective comparative study with vitamin K antagonists. Clin Drug Investig. 2020; 40: 343–353.

21. Guidetti R, Anwar M, Walters RW, Apala D, Pajjuru V, Kousa O, Guijula NR, Alla VM. Treatment of left ventricular thrombus with direct oral anticoagulants: A retrospective observational study. Am J Med. 2020; 133: 1488–1491.

22. Herald J, Goitia J, Duan L, Chen A, Lee MS. Safety and effectiveness of direct Oral anticoagulants versus warfarin for treating left ventricular thrombus. Am J Cardiovasc Drugs. 2022; 22: 437–444.

23. Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail. 2020; 7: 2032–2041.

24. Iskaros O, Marsh K, Papadopoulos J, Mammadhan A, Ahuja T. Evaluation of direct Oral anticoagulants versus warfarin for Intracardiac thromboses. J Cardiovasc Pharmacol. 2021; 77: 621–631.

25. Jones D, Wright P, Alizadeh M, Fahid S, Rathod K, Guttman O, Knight C, Timmis A, Baumbach A, Wragg A, Mathur A, Antoniou S. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction (AMI). Eur Heart J Cardiovasc Pharmacother. 2021; 7: 398–404.

26. McCarthy C, Murphy S, Venkateswaran RV, Singh A, Chang L, Joice MG, Qamar A, Vaduganathan M, Januzzi J, Bhatt DL. Contemporary etiologies, treatment strategies, and outcomes of left ventricular thrombus. J Am Coll Cardiol. 2019; 73: 716.

27. Mihm AE, Hicklin HE, Cunha AL, Nisly SA, Davis KA. Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombosis. Intern Emerg Med. 2021; 16: 2133–2137.

28. Ratnayake C, Liu B, Benatar J, Stewart RAH, Somaratne JB. Left ventricular thrombus after ST segment elevation myocardial infarction: A single-Centre observational study. N Z Med J. 2020; 133: 45–54.

29. Robinson AA, Trankle CR, Eubanks G, Schumann C, Thompson P, Wallace RL, Gottiparthi S, Ruth B, Kramer CM, Salerno M, Bilichik RC, Deen C, Kontos MC, Dent J. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020; 5: 685–692.

30. Varwani MH, Shah J, Naguna M, Jelain M. Treatment and outcomes in patients with left ventricular thrombus-experiences from the aga khan university hospital. Nairobi-Kenya Pan African Medical Journal. 2021; 39: 212.

31. Willeford A, Zhu W, Stevens C, Thomas IC. Direct Oral anticoagulants versus warfarin in the treatment of left ventricular thrombus. Ann Pharmacother. 2021; 55: 839–845.

32. Wu SY, Hwang N, Mohamed Yusof AK, Yusof Z, Loong MS, Wan-Arafah N, Naiing NN. Apixaban versus warfarin in ef fectiveness of direct Oral anticoagulants versus warfarin for the treatment of left ventricular thrombus. ESC Heart Fail. 2020; 7: 2032–2041.
patients with left ventricular thrombus: A pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus. *J Clin Prev Cardiol.* 2020; 9: 150–154.

33. Xu Z, Li XM, Li XW, Gao YP, Mi XL. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus. *Ann Palliat Med.* 2021; 10: 9427–9434.

34. Zhang Z, Si D, Zhang Q, Mu M, Yu M, Jiang Z, Li D, Yang P, Zhang W. Rivaroxaban versus vitamin K antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-elevation myocardial infarction. *Heart Vessels.* 2021.

35. Xuan H, Chen YM, Dai YL, Zhou J, Jiang YF, Zhou YF. Safety and efficacy of vitamin K antagonists vs. novel Oral anticoagulants in patients with left ventricular thrombus: A meta-analysis. *Front Cardiovasc Med.* 2021; 8: 636491.

36. Michael F, Natt N, Shurrab M. Direct Oral anticoagulants vs vitamin K antagonists in left ventricular thrombi: A systematic review and meta-analysis. *CJC Open.* 2021; 3: 1169–1181.

37. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ.* 2009; 339: b2535.

38. Sterne JAC, Savovici J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ.* 2019; 366: i4898.

39. Ottawa Hospital Research Institute. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford/. As accessed January 17, 2021.

40. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5. 1. 0.

41. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour enhanced meta-analysis funnel plots help distinguisish publication bias from other causes of asymmetry. *J Clin Epidemiol.* 2008; 61: 991–996.

42. Sirajuddin A, Mirmomen SM, Kligerman SJ, Groves DW, Burke AP, Kureshi F, White CS, Aral AE. Ischemic heart disease: Noninvasive imaging techniques and findings. *Radiographics.* 2021; 41: 990–1021.

43. Bulluck H, Chan MHH, Paradies V, Yellon RL, Ho HH, Chan MY, Chin CWL, Tan JW, Hausenloy DJ. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis. *J Cardiovasc Magn Reson.* 2018; 20: 72.

44. Pöss J, Desch S, Eitel C, de Waha S, Thiele H, Eitel I. Left ventricular thrombus formation after ST-segment-elevation myocardial infarction: Insights from a cardiac magnetic resonance multicenter study. *Circ Cardiovasc Imaging.* 2015; 8: e003417.

45. Leow AS, Sia C, Tan BY, Chan MY, Loh JP. Characterisation of patients with acute myocardial infarction complicated by left ventricular thrombus. *Eur J Intern Med.* 2020; 74: 110–112.

46. Camaj A, Fuster V, Giustino G, Bienstock SW, Sternheim D, Mehran R, Dangas GD, Kini A, Sharma SK, Halperin J, Dweck MR, Goldman ME. Left ventricular thrombus following acute myocardial infarction: JACC state-of-the-art review. *J Am Coll Cardiol.* 2022; 79: 1010–1022.

47. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JI, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med.* 2011; 365: 883–891.

48. Gagliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinare J, Ruzylo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2013; 369: 2093–2104.

49. Tedla YG, Schwartz SM, Silberman P, Greenland P, Passman RS. Racial disparity in the prescription of anticoagulants and risk of stroke and bleeding in atrial fibrillation patients. *J Stroke Cerebrovasc Dis.* 2020; 29: 104718.

50. Lähteenmäki J, Vuorinen AL, Pajula J, Harno K, Lehto M, Niemi M, Gils MV. Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users. *Clin Pharmacol Ther.* 2021; 110: 768–776.

51. Zhao M, Zhang Q, Wang X, Zhang Q, Tian C, Li R, Jia X, Gu M, Yang L. Non-synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban. *Clin Transl Sci.* 2022; 15: 923–929.

52. Sjögren V, Byström B, Renlund H, Svensson PJ, Oldgren J, Norrving B, Själander A. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. *PloS ONE.* 2017; 12: e0181000.

53. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med.* 2017; 377: 1513–1524.

54. Lopes RD, Heizger R, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med.* 2019; 380: 1509–1524.

55. Zhang J, Wang X, Liu X, Larsen TB, Witt DM, Ye Z, Thabane L, Li G, Lip GYH. Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: A systematic review and meta-analysis. *Eur J Epidemiol.* 2021; 36: 793–812.